73 related articles for article (PubMed ID: 9040722)
1. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD; Dubini A; Orlando N; Grimaldi R
Neurology; 1997 Feb; 48(2):363-8. PubMed ID: 9040722
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KD
Cochrane Database Syst Rev; 2001; 2001(1):CD001519. PubMed ID: 11279721
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; 2001(1):CD001518. PubMed ID: 11279720
[TBL] [Abstract][Full Text] [Related]
4. Fatigue in levodopa-naive subjects with Parkinson disease.
Schifitto G; Friedman JH; Oakes D; Shulman L; Comella CL; Marek K; Fahn S;
Neurology; 2008 Aug; 71(7):481-5. PubMed ID: 18695158
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF-
Huang J; Hong W; Yang Z; Ding J; Ren Y
J Int Med Res; 2020 Jul; 48(7):300060520922449. PubMed ID: 32735501
[TBL] [Abstract][Full Text] [Related]
6. A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Damier P; Degos B; Castelonovo G; Anheim M; Benatru I; Carrière N; Colin O; Defebvre L; Deverdal M; Eusebio A; Ferrier V; Giordana C; Houeto JL; Le Dily S; Mongin M; Thiriez C; Tranchant C; Ravel D; Corvol JC; Rascol O; Ben Ari Y
Mov Disord; 2024 Mar; 39(3):618-622. PubMed ID: 38291616
[TBL] [Abstract][Full Text] [Related]
7. Levodopa use in Australia: an analysis of Pharmaceutical Benefits Scheme 10% data.
Evans A; Waterhouse BJ
BMJ Neurol Open; 2024; 6(1):e000484. PubMed ID: 38268755
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic treatment strategies for people with Parkinson's disease in Europe: a retrospective analysis of PRISM trial data.
Hansen L; Witzig V; Schulz JB; Holtbernd F
Neurol Sci; 2023 Nov; 44(11):3905-3912. PubMed ID: 37311949
[TBL] [Abstract][Full Text] [Related]
9. Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline.
Belmonte Y; de Fàbregues O; Marti M; Domingo C
Open Respir Med J; 2009 Jun; 3():90-3. PubMed ID: 19572029
[TBL] [Abstract][Full Text] [Related]
10. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
[TBL] [Abstract][Full Text] [Related]
11. The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinson's disease: a systematic review and meta-analysis.
Zhao YT; Liu L; Zhao Y; Xie ZY
J Neurol; 2022 Apr; 269(4):1834-1850. PubMed ID: 34652505
[TBL] [Abstract][Full Text] [Related]
12. In Parkinson's patient-derived dopamine neurons, the triplication of α-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition.
Lin M; Mackie PM; Shaerzadeh F; Gamble-George J; Miller DR; Martyniuk CJ; Khoshbouei H
Acta Neuropathol Commun; 2021 Jun; 9(1):107. PubMed ID: 34099060
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).
Sy MAC; Fernandez HH
Neurotherapeutics; 2020 Oct; 17(4):1331-1338. PubMed ID: 32935299
[TBL] [Abstract][Full Text] [Related]
14. Non-human primate models of PD to test novel therapies.
Morissette M; Di Paolo T
J Neural Transm (Vienna); 2018 Mar; 125(3):291-324. PubMed ID: 28391443
[TBL] [Abstract][Full Text] [Related]
15. Management of medically refractory prolactinoma.
Molitch ME
J Neurooncol; 2014 May; 117(3):421-8. PubMed ID: 24146188
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.
Perez-Lloret S; Rascol O
CNS Drugs; 2010 Nov; 24(11):941-68. PubMed ID: 20932066
[TBL] [Abstract][Full Text] [Related]
17. Role of pramipexole in the management of Parkinson's disease.
Antonini A; Barone P; Ceravolo R; Fabbrini G; Tinazzi M; Abbruzzese G
CNS Drugs; 2010 Oct; 24(10):829-41. PubMed ID: 20839895
[TBL] [Abstract][Full Text] [Related]
18. Update on the use of pramipexole in the treatment of Parkinson's disease.
Constantinescu R
Neuropsychiatr Dis Treat; 2008 Apr; 4(2):337-52. PubMed ID: 18728740
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic resistance in prolactinoma patients.
Molitch ME
Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline : a review of its use in the treatment of Parkinson's disease.
Curran MP; Perry CM
Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
